Originally posted by Glyco
@ricky_banker
@omaz
May i suggest yoy check up valuation of another asx-listed healthcare stock (which i dont hold):
It took Pme 5 years to deliver U$25m in revenue
Pme, imaging (x-ray) analytics
Revenue A$35m (U$25m)
Mkt Cap = A$1.22 billions.
https://finance.yahoo.com/quote/PME.AX/key-statistics?p=PME.AX
What is PME's f/c revenue in 6,12, 18 months?
Q&A
1..Can Yacov deliver u$25m to $50m from MOUs signed
2.What is a reasonable valuations for
a.70%Gyim ( SBoletong + Silverlake, 2x MOUs)
b.100% USA/GMedDx
c.100% MK (MEDTL, Cyprus,U$10m Mou)
d.100% HK/Asia ( Taiwan MOU, even if India MOU is delayed)
3.Will those MOUs valued exceed *$25m ?
4 What is GMV f/c revenues in 6 months, 12 months and 18 months?
5. How will UOB and Nasdaq value Gmv?
cheers
please dyor. aimo
This is to show for any start-up: if revenue can grow, then valuation will rise correspondingly, whether it take 5 years,
1 year or 6 months?
PME has 1036m shares
Sp has gone up form 20c to $12 high, in 5 years
.
.
If we shrink Pme shares to half (fully diluted 505 m, simillar to Gmv sh/ops, if good Doc delivers both milestone B & C),
that means
Pme sp has gone from $0.40c to $6 , based on current U$25m (A$35m) revenue,
and
likely f/c revenue of U$40m to $50m in 12 months
aimo
dyor.
